tbuckley/cabot-search huggingface dataset:
SAT0287 What are the economic implications of anti-tnf therapy in patients with axial spondyloarthritis? – results of a health insurance claims data analysis
Authors: I. Redeker, F. Hoffmann, J. Callhoff, H. Haibel, J. Sieper, A. Zink, D. Poddubnyy
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Tumour necrosis factor (TNF)-α inhibitors are an effective but rather expensive treatment option in axial spondyloarthritis (axSpA) patients who fail conventional treatment. <h3>Objectives</h3> The aim of this study was to analyse the changes in healthcare costs and resource utilisation after initiation of TNF-α inhibitors in patients with axSpA. <h3>Methods</h3> Data of patients with axSpA newly exposed to TNF-α inhibitors between January 1, 2011 and December 31, 2015 were studied by using health insurance claims data in Germany. Resource utilisation, direct healthcare costs and productivity costs were assessed. Direct healthcare costs comprised costs for outpatient care (i.e., visits to physicians, laboratory visits, non-physician visits [e.g., visits to physical therapists], emergency department visits, outpatient hospital services, and aids [e.g., walkers]), costs for inpatient care (i.e., inpatient admissions) and costs for pharmacotherapy. Productivity costs comprised costs due to absence from paid work and were calculated using the friction cost method (FCM) and the human capital approach (HCA). Costs and resource utilisation were analysed the year before (baseline period) and the year after (follow-up period) initiation of TNF-α inhibitors. <h3>Results</h3> Data from 1452 persons were included in the analyses; mean age was 44.6 years and 47.9% were female. AxSpA-related pharmacotherapy use (non-steroidal anti-inflammatory drugs [NSAIDs], non-opioid analgesics, opioid analgesics, systemic steroids, local steroids and conventional synthetic disease-modifying anti-rheumatic drugs [csDMARDs]) and admissions to hospital decreased significantly in the follow-up period compared to the baseline period. However, due to anti TNF-α therapy, mean direct healthcare costs increased from € 4494 per patient in the baseline period to € 26 473 per patient in the follow-up period. Mean total costs increased from € 8072 to € 29 959 using the HCA and from € 6377 to € 28 162 using the FCM (Table). Excluding costs for anti-TNF therapy, total costs decreased by 15% to € 6876 or by 20% to € 5080 based on whether the HCA or the FCA was used. <h3>Conclusions</h3> Overall resource utilisation decreased after initiation of TNF-α inhibitors. The rise in pharmacotherapy costs driven by anti-TNF agents is accompanied by significantly lower costs for outpatient and inpatient care, as well as significantly lower productivity costs. However, the effect of TNF-blocker therapy on the patient's disease activity, function or quality of life could not be assessed in this analysis. <h3>Acknowledgements</h3> This work was supported by the Federal Ministry of Education and Research within the research network PROCLAIR (01EC1405). <h3>Disclosure of Interest</h3> None declared
Availability of over-the-counter laxatives should not be restricted
Authors: Peter J Whorwell
Journal: BMJ (2019)

The government is being encouraged to restrict the availability of over-the-counter laxatives because of the risk of misuse by people with eating disorders.12 A further suggestion is that packaging should warn that their long term use is harmful.3 This initiative could have serious unintended consequences.

Many patients with the constipation subtype of irritable bowel syndrome have …
THU0656 Systemic lupus erythematosus in colombia: a bibliometric analysis
Authors: J.E. Barahona-Correa
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a high burden of disease on individuals and healthcare systems.<sup>1</sup> Bibliometric analyses assess scientific literature on a given topic, and allow the identification of novel research trends, based on statistical data of scientific literature and their indicators.<sup>2,3</sup> In Colombia, few efforts have addressed at Rheumatology or Autoimmunity. <h3>Objectives</h3> To perform a bibliometric study on the scientific production on SLE in Colombia that describes its distribution, development trends, national and international collaboration trends, and its impact on the scientific community. <h3>Methods</h3> A descriptive bibliometric study was performed using three databases (Web of Science, SCOPUS and Scielo). Annual national research output, number of articles, city and institution of origin, national and international collaboration, scientific journals, publication language, and citations number were assessed. VOSviewer was used to illustrate collaboration networks. <h3>Results</h3> SCOPUS disclosed 307 articles, Web of Science 270, and Scielo 90. The highest number of citations per item (19.8) and the maximum national H index<sup>41</sup> were found in SCOPUS. More than 80% of articles, regardless of the database, were published during the last 10 years. 'Universidad del Rosario' and 'Universidad de Antioquia' showed the highest research output. Bogotá and Antioquia, followed by Valle del Cauca, presented the highest number of articles. An important number of national and international collaborations were observed, which differed in each database. Abbreviations: WoS Web of Science, SD Standard deviation <h3>Conclusions</h3> A significant growth of the research on SLE in Colombia was observed, however, its impact is far from being meaningful. Strategies aimed at strengthening the interest in Rheumatology and research in undergraduate students must be encouraged, particularly supporting research seedbeds and young researchers. <h3>References</h3> [1] Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Prim2016;2:16039. [2] Ellegaard O, Wallin JA. The bibliometric analysis of scholarly production: How great is the impact?Scientometrics105(3):1809–31. [3] Li BZ, Pan HF, Ye DQ. A bibliometric study of literature on SLE research in PubMed (2002–2011). Lupus2013;22(8):772–7. <h3>Disclosure of Interest</h3> None declared
Abstract 16760: HDL Modulates Cardiac Glucose Metabolism And Inflammation And Improves Cardiac Function After Myocardial Ischemia Reperfusion Injury
Authors: Adele Richart, Sarah E Heywood, Darren C Henstridge, Karen Alt, Helen Kiriazis, Andrew L Carey, Helene Kammoun, Husna Begum, Lea M Delbridge, Peter J Meikle, Christoph E Hagemeyer, Mark A Febbraio, Xiao-Jun Du, Andrew L Siebel, Bronwyn A Kingwell
Journal: Circulation (2016)

Objective: High-density lipoprotein (HDL) has multiple actions which may benefit post-ischemic heart function. We examined the effects of reconstituted HDL (rHDL, CSL-111), delivered immediately fo...
Size Matters: Identification of Larger Size CD19 Positive Extracellular Vesicles in Chronic Lymphocytic Leukemia That Inhibit Chimeric Antigen Receptor T Cell Functions
Authors: Cynthia L. Forsman, Reona Sakemura, Fabrice Lucien-Matteoni, Elizabeth Juarez-Diaz, Nan Yang, Michelle J. Cox, Sutapa Sinha, Mehrdad Hefazi, Kendall J. Schick, Justin C. Boysen, Sameer A. Parikh, Hon Sing Leong, Neil E. Kay, Saad S. Kenderian
Journal: Blood (2018)
Type 1 Diabetes Risk in African-Ancestry Participants and Utility of an Ancestry-Specific Genetic Risk Score
Authors: Suna Onengut-Gumuscu, Wei-Min Chen, Catherine C. Robertson, Jessica K. Bonnie, Emily Farber, Zhennan Zhu, Jorge R. Oksenberg, Steven R. Brant, S. Louis Bridges, Jeffrey C. Edberg, Robert P. Kimberly, Peter K. Gregersen, Marian J. Rewers, Andrea K. Steck, Mary H. Black, Dana Dabelea, Catherine Pihoker, Mark A. Atkinson, Lynne E. Wagenknecht, Jasmin Divers, Ronny A. Bell, Henry A. Erlich, Patrick Concannon, Stephen S. Rich
Journal: Diabetes Care (2019)

Genetic risk scores (GRS) have been developed that differentiate individuals with type 1 diabetes from those with other forms of diabetes and are starting to be used for population screening; however, most studies were conducted in European-ancestry populations. This study identifies novel genetic variants associated with type 1 diabetes risk in African-ancestry participants and develops an African-specific GRS.
Circulating Tumor DNA in Advanced Anal Cancer: A Blood Biomarker Goes Viral
Authors: Van K. Morris
Journal: Clinical Cancer Research (2019)

Circulating tumor DNA (ctDNA) as a blood-based biomarker for mutation detection is an exciting, highly sensitive approach in the clinical management of oncology patients. In human papillomavirus-associated malignancies like anal cancer, a viral-specific probe can be utilized for ctDNA detection in the majority of patients to predict clinical outcomes.See related article by Bernard-Tessier et al., p. 2109.
Prospective Evaluation of Prognostic Relevance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: Results from the JALSG CBF-AML209-KIT Study
Authors: Naomi Kawashima, Yuichi Ishikawa, Yoshiko Atsuta, Isamu Sugiura, Masashi Sawa, Nobuaki Dobashi, Hisayuki Yokoyama, Noriko Doki, Akihiro Tomita, Toru Kiguchi, Shiro Koh, Heiwa Kanamori, Noriyoshi Iriyama, Akio Kohno, Yukiyoshi Moriuchi, Noboru Asada, Daiki Hirano, Kazuto Togitani, Toru Sakura, Maki Hagihara, Tatsuki Tomikawa, Yasuhisa Yokoyama, Norio Asou, Shigeki Ohtake, Itaru Matsumura, Yasushi Miyazaki, Tomoki Naoe, Hitoshi Kiyoi
Journal: Blood (2018)
Oligoadenylate-Synthetase-Family Protein OASL Inhibits Activity of the DNA Sensor cGAS during DNA Virus Infection to Limit Interferon Production
Authors: Arundhati Ghosh, Lulu Shao, Padmavathi Sampath, Baoyu Zhao, Nidhi V. Patel, Jianzhong Zhu, Bharat Behl, Robert A. Parise, Jan H. Beumer, Roderick J. O’Sullivan, Neal A. DeLuca, Stephen H. Thorne, Vijay A.K. Rathinam, Pingwei Li, Saumendra N. Sarkar
Journal: Immunity (2019)
GP patients fear being overheard at “tired, dilapidated, poorly maintained” premises
Authors: Ingrid Torjesen
Journal: BMJ (2019)

Many patients are worried about being overheard by others when they speak to the receptionist at their GP surgery, telephone their practice, or consult with the GP because consulting rooms are not adequately soundproofed, a report by the Patients Association has found.1

Patients also said that surgeries were difficult to access, particularly for disabled people, and that waiting rooms were outdated and too small.

Of the 720 patients who contributed to the report by responding to an online survey or participating in one of four focus groups, 58% said that their practice did not have enough space to allow reasonable privacy, and some found it “impossible” to speak to the …
David Oliver: Ageing, risk, and public perception
Authors: David Oliver
Journal: BMJ (2019)

In last week’s column I discussed some issues raised by the BBC One drama Care .12 The show highlighted different perceptions and attitudes about risk and autonomy in older people who have difficulty managing at home.

Hospital staff were portrayed as desperate to get Jenny’s mother, Mary (Alison Steadman), back into her home after being disabled by a stroke and cognitive impairment. They clearly saw this as the right thing for Mary and for a system under pressure. But, in Jenny’s view, Mary was clearly no longer safe—and short, episodic visits from home care staff, who didn’t know her well, wouldn’t make her so. A nursing home seemed the least bad option.

In 2014 a BBC Two documentary …
AB1470-HPR Beliefs and satisfaction with golimumab as second anti tnf-alpha of patients with spondyloarthritis. go-beyond
Authors: X Juanola, C.M. González Fernández, S. García-Carazo, J. Rodríguez-Hereida, J. Bachiller-Corral, M. Martín López, M. Retuerto Guerrero, J. Martín Santos, N. Álvarez-Rivas, C. Egües Dubuc, I. Villa-Blanco, A. Laiz, J.V. Tovar Beltrán, E. Beltrán, E. Raya, R. Ibáñez Bosch, J. Manero, J. Pons Dolset, B. García Magallón, Y. Mestre, S. Fernández, M. Mosquera, L. Cea-Calvo, J.J. Alegre-Sancho
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> In patients with spondyloarthritis (SpA: axial SpA or psoriatic arthritis [PsA]), treated with golimumab as second biological therapy (after failure or withdrawal of a first anti TNF-α drug), we describe patients' insights with regard to their beliefs and their satisfaction with golimumab therapy. <h3>Methods</h3> Patients on golimumab from GO-BEYOND, a retrospective study undergone in 20 Spanish rheumatology clinics, were requested to respond to the <i>Beliefs About Medicines Questionnaire</i> (BMQ). Statements of the BMQ include a 5-item necessity and a 5-item concern scale with Likert response options from "strongly agree" to "strongly disagree". Patients also responded to questions on their satisfaction and experience with golimumab self-injection. Descriptive data are displayed, and responses to the BMQ in axial SpA vs PsA patients were compared with the chi-square test. <h3>Results</h3> 123 patients on golimumab as second anti TNF-α responded (81 axial SpA and 42 PsA, mean age 49 years [SD=11], 40% women). Patients showed strong beliefs in the necessity of golimumab for the treatment of their SpA (percentages of "agree" or "strongly agree" to the necessity statements: 50%–80%), but also concerns: half the patients agreed/strongly agreed to be worried about long term effects of golimumab, and ≈30% about becoming too dependent on the drug (table 1). Responses were similar in axial SpA and PsA patients (table 1). 111 patients declared to self-inject golimumab. Of these, 22.7% considered the experience with self-injection as very positive, 66.4% as positive, 10.0% neutral and only 0.9% unfavourable, and the use of the device very easy (37.3%), easy (57.3%), neutral (3.6%) and only 1.8% difficult. Finally 36.4% and 49.1% were very satisfied or satisfied with the interval of administration of golimumab, 11.8% were neutral and only 1.8% and 0.9% declared to be dissatisfied or very dissatisfied. <h3>Conclusions</h3> Patients with SpA currently using golimumab as second anti TNF-alpha describe strong beliefs in the necessity of golimumab and good experience and satisfaction with self-administration. The BMQ also identified concerns that should be addressed in the clinic. The study is limited to the subset of patients still on golimumab at the study visit. <h3>Acknowledgements</h3> Funded by Merck Sharp and Dohme, Spain <h3>Disclosure of Interest</h3> None declared
Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma
Authors: Nora Sundahl, Gillian Vandekerkhove, Karel Decaestecker, Annabel Meireson, Pieter De Visschere, Valérie Fonteyne, Daan De Maeseneer, Dries Reynders, Els Goetghebeur, Jo Van Dorpe, Sofie Verbeke, Matti Annala, Lieve Brochez, Kim Van der Eecken, Alexander W. Wyatt, Sylvie Rottey, Piet Ost
Journal: European Urology (2019)
THU0678 Trend of venous thromboembolism among select rheumtologic diseases: an audit of large national us database
Authors: D.R. Poudel, R. Dhital, P. Paudel, S. Basnet, P. Sharma, P. Shrestha, P. Karmacharya
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Venous thromboembolism (VTE) is 3rd commonest cause of cardiovascular deaths and encompasses deep-venous thrombosis (DVT) and pulmonary embolism (PE). Rheumatologic diseases have been found to be associated with an increased risk of VTE among hospitalised patients. <h3>Objectives</h3> To describe the trend of VTE among select rheumatologic diseases over 15 years. <h3>Methods</h3> We used National Inpatient Sample (NIS) database for years 2000–2014 to identify adults≥18 years with select rheumatologic diseases and VTE based on ICD-9 codes. Prevalence was age-sex adjusted against US census population data. STATA was used for querying database and Joinpoint regression was used to analyse annual trends of prevalence in terms of annual percentage change (APC). Logistic regression with survey command was used to derive adjusted odds of VTE association for all years combined. <h3>Results</h3> We included a total of 461,089,203 hospitalizations among which 8,822,456 (1.91%) had VTE (table 1). An upward trend in the prevalence of VTE (APCs 2.45–4.16) (and PE subset) was noted in most of the rheumatologic disease groups (figure 1). DVT, however, had a decreasing or non-significant increasing trend among most disease groups (data for DVT and PE not shown). The adjusted odds of VTE association was highest among SLE group (aOR=2.2, CI=2.17–2.3) followed by DM/PM (aOR=2.0, CI=1.9–2.2) (table 1). Table 1 Frequency counts of rheumatologic diseases and controls; prevalence of VTE and adjusted regression analysis of VTE association <h3>Conclusions</h3> Inflammatory rheumatologic diseases seem to be associated with higher prevalence and odds of having VTE among hospitalised patients and the overall trend is rising. This might indicate some lag in following of guidelines for VTE prophylaxis. Closer look into the implications of stricter prophylaxis among rheumatologic patients is a matter of further studies. <h3>Disclosure of Interest</h3> None declared
OP0090 Mitochondrial dna mutations and respiratory chain dysfunction in lung fibrosis of systemic sclerosis
Authors: V.K. Jaeger, D. Lebrecht, A.G. Nicholson, A.U. Wells, S. George, A. Gazdhar, M. Tamm, N. Venhoff, T. Geiser, U.A. Walker
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Recent data have implemented reactive oxygen species (ROS) in the etiology of interstitial lung disease (ILD) in systemic sclerosis. <h3>Objectives</h3> To investigate a role of large-scale somatically acquired mutations in mitochondrial DNA (mtDNA) and consecutive respiratory chain dysfunction as a trigger of ROS formation and lung fibrosis. <h3>Methods</h3> Lung biopsies from patients with idiopathic interstitial pneumonitis and systemic sclerosis (n=31) were analysed for mitochondrial functions and compared with biopsies from 13 healthy controls (HC). From 17 patients we had simultaneous biopsies from the upper and lower lung. <h3>Results</h3> Malondialdehyde as a marker of ROS formation was increased in ILD (p=0.007). The median proportion of mtDNA containing the pathogenic common deletion was 22.5% in ILD patients, compared to 0% in HC. This translated into a 3.8-fold diminishment of mtDNA-encoded cytochrome c-oxidase (COX2), but not nucleus-encoded (COX4) respiratory chain subunits in ILD compared to controls (p&lt;0.0001) and a 33% diminishment of mtDNA-encoded cytochrome c-oxidase activity (p=0.001 vs controls). In all patients, the more fibrotic lower lungs had significantly more malondialdehyde (p=0.0004), mtDNA deletions (p=0.0006), and cytochrome c-oxidase dysfunction (p=0.0003) than the less-fibrotic upper lung counterparts. Conversely, lower lungs had significantly less (p=0.0003) mtDNA-encoded COX2 subunits in comparison to non-mtDNA-encoded COX4 subunits (figure 1). There was no association of any mitochondrial parameter with smoking status or age, and no difference between biopsies from patients with systemic sclerosis and non-specific interstitial pneumonitis. <h3>Conclusions</h3> Our data support a role of mtDNA-mutations and consecutive respiratory chain dysfunction as a trigger and perpetuator of ROS formation in both, idiopathic interstitial pneumonitis and ILD of patients with systemic sclerosis. <h3>Disclosure of Interest</h3> None declared
AB0786 Role of calcium antagonists in the cancer of systemic sclerosis, an association under discussion
Authors: M. Freire, A. Cabaleiro, M. Suarez, M. Estevez, L. Rodríguez, J.M. Cacheiro, R. Lorenzo, N. Val, A. Argibay, A. Rivera
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The use of calcium channel blockers (CCB) is widespread in systemic sclerosis (SSc) for the treatment of Raynaud's phenomenon, present in 95% of patients. CCB can alter apoptosis, a mechanism for the destruction of cancer cells. In SSc the risk of cancer is increased, but the role that CCB can play is not clear, with contradictory data obtained so far.<sup>1,2</sup> <h3>Objectives</h3> To analyse the role of CCB in the appearance of cancer in a cohort of patients with systemic sclerosis. <h3>Methods</h3> Encoded patients under the diagnosis of SSc in our hospital from 1985 until December of 2017 were collected. Medical records were reviewed, recording clinico-epidemiological data and treatments used. <h3>Results</h3> 120 patients have been diagnosed of SSc (103 females, 17 males), 22 of whom (18,3%) have developed cáncer. The type of cáncer were (in order of frecuency): breast (12 patients, 57%), gastrointestinal (4 patients, 33%), one hypernephroma, one endometrial carcinoma, one lyphoma, one skin cáncer and one epidermoid of tongue. Adenocarcinoma was the most frequently histologic pattern found (16 patients, 76%). Interestingly, the diagnosis of SSc was made at an older age in those patients diagnosed of cáncer (66,4±11,7 vs 54,8±17,3 years old, p=0,019); An age older than 55 years old conferred a relative risk (RR) of cáncer of 1,69<sup>1,26–2,25</sup> in the global cohort and a RR of 3,26<sup>1,18–8,99</sup> in the female cohort. Although the association cancer and CCB did not reach statistical significance, the association CCB and female patients older tan 55 years elevate de RR of cáncer to 4,16 (0.96–17,95). All other characteristics (epidemioloical, clinical, analytical and another treatments) analized did not reach statistical significant differences. <h3>Conclusions</h3> CCB increase in our series the risk of cancer in women over 55 yeras old. CCB could be implicated in the patogenia of cáncer in SSc. Due to the broad use of this in the SSc population, it may be require to study in a large number of patients in order to explore this association. <h3>References</h3> [1] Colaci M, et al. Breast cancer in systemic sclerosis: Results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature. Autoimmunity Reviews2014, 13(2): 132–137 [2] Bernal-Bello D, et al. Novel risk factors related to cancer in scleroderma,Autoimmunity Reviews2017, doi: 10.1016/j.autrev.2017.03.012 <h3>Disclosure of Interest</h3> None declared
Osteogenic magnesium incorporated into PLGA/TCP porous scaffold by 3D printing for repairing challenging bone defect
Authors: Yuxiao Lai, Ye Li, Huijuan Cao, Jing Long, Xinluan Wang, Long Li, Cairong Li, Qingyun Jia, Bin Teng, Tingting Tang, Jiang Peng, David Eglin, Mauro Alini, Dirk W. Grijpma, Geoff Richards, Ling Qin
Journal: Biomaterials (2019)